Cargando…
Managing Lung Cancer with Comorbid Interstitial Pneumonia
Systemic therapy for advanced non-small cell lung cancer (NSCLC) has dramatically changed in the latest 15 years. Molecular-targeted therapy has brought about an era of precision medicine, and immune checkpoint inhibitors have brought hope for a cure for advanced NSCLC. In the wake of this remarkabl...
Autores principales: | Ichihara, Eiki, Miyahara, Nobuaki, Maeda, Yoshinobu, Kiura, Katsuyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008037/ https://www.ncbi.nlm.nih.gov/pubmed/31534086 http://dx.doi.org/10.2169/internalmedicine.3481-19 |
Ejemplares similares
-
Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review
por: Itano, Junko, et al.
Publicado: (2019) -
Interstitial Pneumonia Secondary to Hermansky-Pudlak Syndrome Type 4 Treated with Different Antifibrotic Agents
por: Itano, Junko, et al.
Publicado: (2020) -
Intravenous immunoglobulin for acute exacerbation of fibrotic idiopathic interstitial pneumonias
por: Higo, Hisao, et al.
Publicado: (2022) -
Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer
por: Ichihara, Eiki, et al.
Publicado: (2018) -
Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease
por: Okawa, Sachi, et al.
Publicado: (2021)